IDEAS home Printed from https://ideas.repec.org/a/wly/riskan/v26y2006i6p1507-1531.html

The Costs of Future Polio Risk Management Policies

Author

Listed:
  • Radboud J. Duintjer Tebbens
  • Nalinee Sangrujee
  • Kimberly M. Thompson

Abstract

Decisionmakers need information about the anticipated future costs of maintaining polio eradication as a function of the policy options under consideration. Given the large portfolio of options, we reviewed and synthesized the existing cost data relevant to current policies to provide context for future policies. We model the expected future costs of different strategies for continued vaccination, surveillance, and other costs that require significant potential resource commitments. We estimate the costs of different potential policy portfolios for low‐, middle‐, and high‐income countries to demonstrate the variability in these costs. We estimate that a global transition from routine immunization with oral poliovirus vaccine (OPV) to inactivated poliovirus vaccine (IPV) would increase the costs of managing polio globally, although routine IPV use remains less costly than routine OPV use with supplemental immunization activities. The costs of surveillance and a stockpile, while small compared to routine vaccination costs, represent important expenditures to ensure adequate response to potential outbreaks. The uncertainty and sensitivity analyses highlight important uncertainty in the aggregated costs and demonstrates that the discount rate and uncertainty in price and administration cost of IPV drives the expected incremental cost of routine IPV vs. OPV immunization.

Suggested Citation

  • Radboud J. Duintjer Tebbens & Nalinee Sangrujee & Kimberly M. Thompson, 2006. "The Costs of Future Polio Risk Management Policies," Risk Analysis, John Wiley & Sons, vol. 26(6), pages 1507-1531, December.
  • Handle: RePEc:wly:riskan:v:26:y:2006:i:6:p:1507-1531
    DOI: 10.1111/j.1539-6924.2006.00842.x
    as

    Download full text from publisher

    File URL: https://doi.org/10.1111/j.1539-6924.2006.00842.x
    Download Restriction: no

    File URL: https://libkey.io/10.1111/j.1539-6924.2006.00842.x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Radboud J. Duintjer Tebbens & Mark A. Pallansch & Olen M. Kew & Victor M. Cáceres & Hamid Jafari & Stephen L. Cochi & Roland W. Sutter & R. Bruce Aylward & Kimberly M. Thompson, 2006. "Risks of Paralytic Disease Due to Wild or Vaccine‐Derived Poliovirus After Eradication," Risk Analysis, John Wiley & Sons, vol. 26(6), pages 1471-1505, December.
    2. Esther De Gourville & Radboud J. Duintjer Tebbens & Nalinee Sangrujee & Mark A. Pallansch & Kimberly M. Thompson, 2006. "Global Surveillance and the Value of Information: The Case of the Global Polio Laboratory Network," Risk Analysis, John Wiley & Sons, vol. 26(6), pages 1557-1569, December.
    3. repec:wbk:wbpubs:13890 is not listed on IDEAS
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Kimberly M. Thompson & Radboud J. Duintjer Tebbens, 2006. "Retrospective Cost‐Effectiveness Analyses for Polio Vaccination in the United States," Risk Analysis, John Wiley & Sons, vol. 26(6), pages 1423-1440, December.
    2. Kimberly M. Thompson & Dominika A. Kalkowska, 2021. "Potential Future Use, Costs, and Value of Poliovirus Vaccines," Risk Analysis, John Wiley & Sons, vol. 41(2), pages 349-363, February.
    3. Radboud J. Duintjer Tebbens & Kimberly M. Thompson, 2018. "Using integrated modeling to support the global eradication of vaccine‐preventable diseases," System Dynamics Review, System Dynamics Society, vol. 34(1-2), pages 78-120, January.
    4. Kimberly M. Thompson, 2006. "Poliomyelitis and the Role of Risk Analysis in Global Infectious Disease Policy and Management," Risk Analysis, John Wiley & Sons, vol. 26(6), pages 1419-1421, December.
    5. Kimberly M. Thompson, 2013. "Modeling Poliovirus Risks and the Legacy of Polio Eradication," Risk Analysis, John Wiley & Sons, vol. 33(4), pages 505-515, April.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Kimberly M. Thompson & Mark A. Pallansch & Radboud J. Duintjer Tebbens & Steve G. Wassilak & Stephen L. Cochi, 2013. "Modeling Population Immunity to Support Efforts to End the Transmission of Live Polioviruses," Risk Analysis, John Wiley & Sons, vol. 33(4), pages 647-663, April.
    2. Kimberly M. Thompson, 2013. "Modeling Poliovirus Risks and the Legacy of Polio Eradication," Risk Analysis, John Wiley & Sons, vol. 33(4), pages 505-515, April.
    3. Kimberly M. Thompson & Dominika A. Kalkowska & Kamran Badizadegan, 2021. "No Role for Reintroducing OPV into the United States with Respect to Controlling COVID‐19 [Response to the letter to the Editor by Chumakov et al.]," Risk Analysis, John Wiley & Sons, vol. 41(2), pages 389-392, February.
    4. Radboud J. Duintjer Tebbens & Mark A. Pallansch & Olen M. Kew & Roland W. Sutter & R. Bruce Aylward & Margaret Watkins & Howard Gary & James Alexander & Hamid Jafari & Stephen L. Cochi & Kimberly M. T, 2008. "Uncertainty and Sensitivity Analyses of a Decision Analytic Model for Posteradication Polio Risk Management," Risk Analysis, John Wiley & Sons, vol. 28(4), pages 855-876, August.
    5. Kimberly M. Thompson, 2006. "Poliomyelitis and the Role of Risk Analysis in Global Infectious Disease Policy and Management," Risk Analysis, John Wiley & Sons, vol. 26(6), pages 1419-1421, December.
    6. Kimberly M. Thompson & Dominika A. Kalkowska, 2021. "Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame," Risk Analysis, John Wiley & Sons, vol. 41(2), pages 229-247, February.
    7. Kimberly M. Thompson & Mark A. Pallansch & Radboud J. Duintjer Tebbens & Steve G. Wassilak & Jong‐Hoon Kim & Stephen L. Cochi, 2013. "Preeradication Vaccine Policy Options for Poliovirus Infection and Disease Control," Risk Analysis, John Wiley & Sons, vol. 33(4), pages 516-543, April.
    8. Kimberly M. Thompson & Dominika A. Kalkowska, 2021. "An Updated Economic Analysis of the Global Polio Eradication Initiative," Risk Analysis, John Wiley & Sons, vol. 41(2), pages 393-406, February.
    9. Kimberly M. Thompson & Dominika A. Kalkowska, 2021. "Potential Future Use, Costs, and Value of Poliovirus Vaccines," Risk Analysis, John Wiley & Sons, vol. 41(2), pages 349-363, February.
    10. Dominika A. Kalkowska & Kimberly M. Thompson, 2021. "Modeling Undetected Live Poliovirus Circulation After Apparent Interruption of Transmission: Borno and Yobe in Northeast Nigeria," Risk Analysis, John Wiley & Sons, vol. 41(2), pages 303-311, February.
    11. Kamran Badizadegan & Dominika A. Kalkowska & Kimberly M. Thompson, 2023. "Health Economic Analysis of Antiviral Drugs in the Global Polio Eradication Endgame," Medical Decision Making, , vol. 43(7-8), pages 850-862, October.
    12. Radboud J. Duintjer Tebbens & Mark A. Pallansch & Dominika A. Kalkowska & Steven G. F. Wassilak & Stephen L. Cochi & Kimberly M. Thompson, 2013. "Characterizing Poliovirus Transmission and Evolution: Insights from Modeling Experiences with Wild and Vaccine‐Related Polioviruses," Risk Analysis, John Wiley & Sons, vol. 33(4), pages 703-749, April.
    13. Radboud J. Duintjer Tebbens & Kimberly M. Thompson, 2018. "Using integrated modeling to support the global eradication of vaccine‐preventable diseases," System Dynamics Review, System Dynamics Society, vol. 34(1-2), pages 78-120, January.
    14. Radboud J. Duintjer Tebbens & Mark A. Pallansch & Konstantin M. Chumakov & Neal A. Halsey & Tapani Hovi & Philip D. Minor & John F. Modlin & Peter A. Patriarca & Roland W. Sutter & Peter F. Wright & S, 2013. "Expert Review on Poliovirus Immunity and Transmission," Risk Analysis, John Wiley & Sons, vol. 33(4), pages 544-605, April.
    15. Kimberly M. Thompson & Radboud J. Duintjer Tebbens, 2006. "Retrospective Cost‐Effectiveness Analyses for Polio Vaccination in the United States," Risk Analysis, John Wiley & Sons, vol. 26(6), pages 1423-1440, December.
    16. Kimberly M. Thompson & Radboud J. Duintjer Tebbens & Mark A. Pallansch & Olen M. Kew & Roland W. Sutter & R. Bruce Aylward & Margaret Watkins & Howard Gary & James P. Alexander & Linda Venczel & Denis, 2006. "Development and Consideration of Global Policies for Managing the Future Risks of Poliovirus Outbreaks: Insights and Lessons Learned Through Modeling," Risk Analysis, John Wiley & Sons, vol. 26(6), pages 1571-1580, December.
    17. Radboud J. Duintjer Tebbens & Mark A. Pallansch & Konstantin M. Chumakov & Neal A. Halsey & Tapani Hovi & Philip D. Minor & John F. Modlin & Peter A. Patriarca & Roland W. Sutter & Peter F. Wright & S, 2013. "Review and Assessment of Poliovirus Immunity and Transmission: Synthesis of Knowledge Gaps and Identification of Research Needs," Risk Analysis, John Wiley & Sons, vol. 33(4), pages 606-646, April.
    18. Radboud J. Duintjer Tebbens & Mark A. Pallansch & Stephen L. Cochi & Derek T. Ehrhardt & Noha H. Farag & Stephen C. Hadler & Lee M. Hampton & Maureen Martinez & Steve G.F. Wassilak & Kimberly M. Thomp, 2018. "Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations," Risk Analysis, John Wiley & Sons, vol. 38(8), pages 1701-1717, August.
    19. R. Bruce Aylward & Roland W. Sutter & Steve L. Cochi & Kimberly M. Thompson & Hamid Jafari & David Heymann, 2006. "Risk Management in a Polio‐Free World," Risk Analysis, John Wiley & Sons, vol. 26(6), pages 1441-1448, December.
    20. Radboud J. Duintjer Tebbens & Mark A. Pallansch & Jong‐Hoon Kim & Cara C. Burns & Olen M. Kew & M. Steven Oberste & Ousmane M. Diop & Steven G.F. Wassilak & Stephen L. Cochi & Kimberly M. Thompson, 2013. "Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling the Risks of Circulating Vaccine‐Derived Polioviruses (cVDPVs)," Risk Analysis, John Wiley & Sons, vol. 33(4), pages 680-702, April.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:wly:riskan:v:26:y:2006:i:6:p:1507-1531. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: https://doi.org/10.1111/(ISSN)1539-6924 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.